Astex Pharmaceuticals Inc has confirmed that it will be halting the development of experimental small-cell lung cancer drug, Amuvatinib. The reason is that the drug failed to achieve a high response rate on an ongoing study. The main goal of the trial, known as ESCAPE, was to evaluate if the drug achieved a response rate of 10 percent. However Amuvatinib was able to achieve a rate of only 9.5 percent. The company said in a statement that no new safety issues ...Saturday, 22 September 2012
Astex Pharma Announces It Will Halt Development of Lung Cancer Drug
Astex Pharmaceuticals Inc has confirmed that it will be halting the development of experimental small-cell lung cancer drug, Amuvatinib. The reason is that the drug failed to achieve a high response rate on an ongoing study. The main goal of the trial, known as ESCAPE, was to evaluate if the drug achieved a response rate of 10 percent. However Amuvatinib was able to achieve a rate of only 9.5 percent. The company said in a statement that no new safety issues ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment